摘要
HTA可科学识别创新高值医用耗材的临床价值,为医保准入决策提供循证依据.我国医用耗材领域HTA起步较晚,尚无成熟的指南或应用规范.综合域内外分析,建议我国可探索分类评估,对"创新程度高""治疗费用高""基金影响大"的创新高值耗材开展HTA.同时,关注耗材特殊性,差异化设计HTA的技术要点,更多选择空白参照、参考真实世界数据、使用成本结果分析(CCA)、考量培训/维护成本等参数、考虑学习曲线效应等.在准入决策时,以辅助决策为主,在少数评估结果足够完善、市场较为稳定的情况下,考虑HTA评估结果作为主要决策依据.
Abstract
Health technology assessment(HTA)can scientifically identify the clinical value of innovative high-value consumables and provide an evidence-based basis for health insurance access decision-making.HTA in the field of medical consumables starts late in China,and there are no mature guidelines or application specifications.Based on the analysis at home and abroad,it is suggested that we can explore the classification of assessment,and carry out HTA for innovative high-value consumables with high degree of innovation,high therapeutic cost,and significant impact on the fund.At the same time,we should pay attention to the special characteristics of consumables,differentiate the design of the key techniques of HTA,choose more blank references,refer to real-world data,use cost-consequence analysis(CCA),consider parameters such as training/maintenance costs,and consider the effects of learning curve.When making decisions on medical insurance access,HTA should be used to assist decision-making,and in a few cases where the assessment results are sufficiently sound and the market is stable,the results of the HTA can be considered as the main basis for decision-making.
NETL
NSTL
万方数据